Podcasts about Prostate cancer

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Brian Custer.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Brian Custer.

Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast.   In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent FDA approvals in the GU space: PROTEUS:  trial comparing ADT monotherapy to apalutamide plus ADT in high-risk localized prostate cancer. We explored its findings, implications, and the ongoing debate surrounding its control arm. TALAPRO-3 Study: impact of PARP inhibitors combined with enzalutamide in metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) mutations. We discussed the nuances of HRR mutations and their clinical significance. CAPITELLO-281: insights into the recent approval of this AKT inhibitor for metastatic castration-sensitive prostate cancer with PTEN loss, based on the CAPItello-281 study. EV-302 update: combination of EV-pembrolizumab still maintains the doubling of survival benefit with longterm follow up. POTOMAC: durvalumab + BCG induction therapy for high-risk non-muscle invasive bladder cancer (NMIBC) could be a choice for a selected patient population. LITESPARK-022: The new approval of belzutifan with pembrolizumab in the adjuvant setting, discussing its efficacy and the importance of patient selection.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o ' Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Throughout the episode, we emphasized the importance of balancing treatment benefits with potential adverse events, as well as the need for shared decision-making in clinical practice. #GUOncology, #ASCO2026, #ProstateCancer, #BladderCancer, #RenalCellCarcinoma, #OncologyBrothers

In this EAU Podcast episode, Ass. Prof. Giancarlo Marra (IT), Prof. Derya Tilki (DE) and Prof. Philip Cornford (IE) discuss the latest updates in the 2026 EAU Guidelines on Prostate Cancer.They explore changes in risk stratification, the evolving role of enzalutamide plus ADT in high-risk disease, and emerging diagnostic technologies such as micro-ultrasound and NeuroSAFE. The conversation also highlights advances in personalised treatment approaches for metastatic hormone-sensitive prostate cancer, including BRCA and PTEN-targeted strategies.In addition, the speakers emphasise the growing importance of supportive care, bone protection, and managing long-term treatment-related side effects to improve patient outcomes.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In a hot seat coaching session on the #amwriting podcast, Jennie Nash coaches Brenna Humphries on a nonfiction proposal for Where It Hurts: A Couple's Guide to Kicking Prostate Cancer, noting a disconnect between the proposal's tone/claims and the sample chapters. They discuss how “salesy” positioning and language that can read as antagonistic toward the medical system may create legal and traditional publishing risks, especially when offering what could be construed as medical advice. Nash suggests shifting authority to lived experience and reframing the book as a framework for how couples navigate diagnosis and decision-making—using structures like key decisions, conversations, or “dates”—while keeping strong scene-based storytelling. Brenna agrees to substantially revise, aiming for a helpful stance that supports patients and partners with questions to ask, teamwork, and process rather than prescriptive medical directives.#AmWriting is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.Join the Blueprint Summer ChallengeStarting a book? Stuck in a draft? Planning a revision?The Blueprint Summer Challenge is designed to help you make meaningful progress on your manuscript this summer.Over six weeks, beginning July 10, you'll use the Blueprint—a proven framework for developing stronger books with greater clarity, purpose, and reader impact—to move your project forward, wherever you are in the process.Whether you're writing nonfiction, memoir, fiction, or another genre entirely, the goal is simple: spend six focused weeks making your book stronger.Start with the Blueprint CourseWe're offering an all-new Blueprint course in Teachable, which includes:The full text of The BlueprintFourteen video lessons covering every step of the frameworkReal coaching examples that show writers applying the Blueprint to their own projectsPractical guidance you can use immediatelyThe course is designed to help you develop a stronger foundation for your book—whether you're beginning from a blank page, working through a draft, or planning a revision.Course enrollment: $19

A new high-resolution MRI is offering a safer way to detect prostate cancer by helping doctors avoid risky biopsies that can lead to complications.

This Men's Health Month, Navigating Cancer TOGETHER sits down with Clarence Jones, prostate cancer survivor and one of Minnesota's most trusted names in community health.Clarence Jones, MA, CHW, CPH, CPE, is the Executive Director and Community Health Strategist of the Hue-MAN Partnership, a founding member of the organization he helped build into one of Minnesota's most trusted voices in public health. He serves as an Adjunct Instructor of Medicine at Mayo Clinic, is a founding member of the Minnesota Fathers and Families Network, has served as the Mayor's Representative and co-chair of the Public Health Advisory Committee for the City of Minneapolis, and holds affiliations with the CTSI Executive Leadership team and the University of Minnesota's CEARCH initiative. He is also a fatherhood doula, the host of the Community Health Dialogue radio show on KMOJ 89.9 FM, and co-host of the Health Chatter podcast.In this warm, honest, and personal conversation, Clarence opens up about his own journey through prostate cancer, from watching his PSA numbers climb year after year and practicing watchful waiting, to eventually choosing surgery. He shares why the digital exam scares men, and why early detection is the greatest gift you can give your family.But Clarence's story doesn't stop at survival. He shares how his experience deepened his mission to make sure the men and families in his community have access to credible, culturally relevant, evidence-based health information. That's the heartbeat of everything Hue-MAN does.You'll also hear him talk about what he wants every man facing a cancer diagnosis to know right now.✨ Episode Highlights:00:04:38 The Moment He Knew: Clarence's Prostate Cancer Journey00:09:22 How to Invite Men into Health Conversations Without Lecturing Them00:14:44 What Young Men Need to Know About PSA Screening and Biopsies00:27:45 Fatherhood Doula: What That Means and Why Fathers Matter00:36:55 What 'Navigating Cancer TOGETHER' Really MeansTranscript: https://bit.ly/podscript184Connect & Engage with ClarenceWebsite: www.huemanpartnershipalliance.orgHealth Chatter Podcast: www.healthchatterpodcast.comKMOJ Community Health Dialogue: 89.9 KMOJ FM

This podcast features two of the investigators from the international, randomized, Phase III EMBARK trial (NCT02319837) in conversation. EMBARK evaluated the efficacy and safety of enzalutamide plus androgen deprivation therapy and enzalutamide monotherapy, as compared with androgen deprivation therapy alone, in patients with nonmetastatic castration-sensitive prostate cancer and biochemical recurrence at high risk for metastasis. In this podcast, the second in the EMBARK series, the speakers discuss the key efficacy and safety findings from the trial, consider some of the patient-reported outcomes and their implications for quality of life, and review some of the implications for clinical practice.

Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12) Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54) Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49) Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath (1:13:12) Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad (1:37:26) CME information and select publications

What Causes Cancer? The Truth Most Doctors Don't Talk AboutIn this episode of Intellectual Medicine, Dr. Stephen Petteruti explores the relationship between cancer, metabolism, sugar, insulin, body fat, and prostate cancer progression. He discusses the Warburg theory, which suggests that cancer may begin with dysfunctional mitochondrial metabolism, and compares it with the later focus on genetic causes of cancer. While he argues that the idea of “starving cancer” by eliminating sugar is too simplistic, he also emphasizes that metabolic health plays a real role in cancer risk and progression.The episode focuses heavily on prostate cancer, which Dr. Petteruti describes as unique compared with other cancers. He argues that conventional approaches often overlook the environment in which cancer develops, including excess body fat, high insulin, elevated blood sugar, inflammation, and poor metabolic health. He also discusses tests such as fasting insulin, hemoglobin A1c, and continuous glucose monitoring, as well as the importance of nutritional and behavioral change. The episode closes with a warning against extreme diets, oversimplified supplement advice, and one-size-fits-all cancer theories.Timestamps:(00:00) What Causes Cancer?(01:02 )The Warburg Theory(02:14) Genetics vs. Metabolism(04:22) Why “Starving Cancer” Is Too Simplistic(05:42) Body Fat, Insulin, and Prostate Cancer(08:30) Tests That May Help Assess Metabolic Health(10:47) Food, Weight Loss, and Cancer Risk(13:42) The Anti-Cancer Lifestyle(15:04) Toxins, Viruses, and Parasites(16:15) NAD, Mitochondria, and Supplement Caution(17:33) Growth Hormone, IGF-1, and Cancer Risk(19:12) Why Extreme Dieting Is Not the AnswerEnjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a board-certified physician specializing in longevity-focused, integrative medicine. He works with men navigating prostate cancer, testosterone, and hormone health, aging, and performance using proactive, evidence-informed strategies grounded in real clinical practice. His approach prioritizes preserving function, strength, and quality of life while helping patients make clear, informed decisions beyond reactive, fear-driven care.Book: Fight Cancer Like a Man: https://tinyurl.com/FightLikeAManBookDr. Steve's email newsletter: https://drstephenpetteruti.substack.com/subscribePodcast show notes : https://www.intellectualmedicine.com/podcast-notesMember exclusive content: https://tinyurl.com/DrPetterutiMemberLearn more: https://www.drstephenpetteruti.com/ Learn more: https://www.intellectualmedicine.com/ Connect with Dr. Petteruti on:⁠Instagram: ⁠https://www.instagram.com/dr.stephenpetteruti/⁠ Facebook: ⁠https://www.facebook.com/dr.stephenpetteruti⁠ Disclaimer:The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.

Prostate cancer is the most commonly diagnosed cancer among men and remains a leading cause of cancer-related death worldwide. While age, family history, and genetics are well-established risk factors, researchers have increasingly focused on the role of metabolic health in prostate cancer progression. Obesity, insulin resistance, type 2 diabetes, and chronic inflammation have all been associated with more aggressive disease, but the molecular mechanisms connecting these conditions to prostate cancer remain incompletely understood. A research paper titled “Epigenetic dysregulation and biological function of PDX1 in prostate cancer” was published in Volume 17 of Oncotarget. In this study, the researchers investigated whether a gene best known for regulating pancreatic function may also play an important role in prostate tumor biology. The study was led by first author Tayo A. Adeyika and corresponding author Bernard Kwabi-Addo from Howard University, Washington, DC. Full blog - https://www.oncotarget.org/2026/06/16/pdx1-may-link-metabolic-dysfunction-to-prostate-cancer-progression/ DOI - https://doi.org/10.18632/oncotarget.28854 Correspondence to - Bernard Kwabi-Addo - bkwabi-addo@howard.edu Abstract video - https://www.youtube.com/watch?v=itYVsyXJJoE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28854 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PDX1, DNA methylation prostate cancer, shRNA knockdown, over-expression, glucose To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this episode of The Penis Project Podcast, Melissa sits down with Don and Clare, a couple who have lived through the messy, emotional and often under discussed reality of prostate cancer recovery.  Don was diagnosed just before his 65th birthday after his PSA rose from around 4 to over 9. A biopsy showed aggressive Gleason 9 prostate cancer, and within six weeks his prostate was removed. His PSA is now undetectable, which is the result everyone hopes for. But, as Don and Clare explain, being “cancer-free” did not mean life went back to normal.   After surgery, Don experienced severe ongoing urinary incontinence. Despite doing all the pelvic floor exercises and following instructions, he was still incontinent 18 months later. Eventually, after further review, he was referred for an artificial urinary sphincter, which has made a huge difference to his quality of life.   This episode is about more than leakage, pads, clips and surgery. It is about what happens when a man feels lost in the medical system. It is about the emotional toll of prostate cancer on both partners. It is about the importance of honesty, asking questions, changing teams if needed, and remembering that there is a person attached to the prostate.  In This Episode, We Cover:  The emotional impact of severe urinary leakage   Why pelvic floor exercises do not fix every case of incontinence   What can be done when continence doesn't recover  Clare's perspective as a partner watching Don struggle   How hormone therapy affected Don's mood, personality and relationship   The importance of being told the full picture, not just the “curative” plan   Why some men need an artificial urinary sphincter   The importance of second opinions and finding a team that sees the whole person   Why prostate cancer recovery is a couple's issue, not just a man's issue    Key Takeaway: An undetectable PSA is wonderful, but it is not the whole story; quality of life matters.    Key message from Don and Clare:   People need honest information.  Don and Clare do not regret the cancer treatment. Don says the surgery likely saved his life. But they both wish they had been told earlier that his continence recovery was unlikely to happen without further intervention. Clare explains that people may not want bad news, but they do want the truth.  That truth gives people options. It helps them plan. It helps them understand that they are not failing. And it can prevent months, or even years, of unnecessary suffering.    Resources & Links:  Book a telehealth consult with our sexual health nurse practitioners at Restorative Health Clinic  For more information check out our websites www.rshealth.com.au , www.makehardeasy.com.au and www.melissahadleybarrett.com.au   Listen & Subscribe  If you found this episode helpful, don't forget to subscribe, rate, and review the podcast! Your feedback helps us continue bringing important conversations to light. Search for The Penis Project Podcast on Spotify, Apple Podcasts, or your favourite podcast app.  Connect With Us   We love hearing from real people navigating penile health. If you'd like to share your journey or ask a question, get in touch.     Email: admin@melissahadleybarrett.com    Websites:  https://rshealth.com.au/  All genders  https://makehardeasy.com.au   https://melissahadleybarrett.com   http://prost.com.au/   Instagram:  https://www.instagram.com/melissahadleybarrett/  https://www.instagram.com/restorativehealth.clinic/    YouTube: https://www.youtube.com/@melissahadleybarrett   TikTok: @melissahadleybarrett    Facebook:  https://m.facebook.com/p/Melissa-Hadley-Barrett-100085237672685/  https://www.facebook.com/profile.php?id=100085146627814    Linkedin:  https://www.linkedin.com/in/melissa-hadley-barrett/   TEDX  https://www.youtube.com/watch?v=IjHj1YTmLoA   

Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.

Kevin Boston-Hill speaks with Naismith Basketball Hall of Famer Nancy Lieberman, and Chief Philanthropy Officer of the Prostate Cancer Foundation, Lori Tessel, about how important it is to have prostate cancer screening. Those who get screened and detect the cancer early have a 99% survival rate.

AUA Guidelines: Clinically Localized Prostate Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: James Eastham, MD, FACS To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/clinically-localized-prostate-cancer

Prostate cancer treatment can bring lasting physical and emotional changes — and many men are caught off guard by how long recovery actually takes. Here is what to expect and how peer support helps. To learn more, visit https://prostaid.org/meetings/ Prostaid Calgary City: Calgary Address: 1600 90 Avenue Southwest Website: https://prostaid.org/

Learn about the Healing Power of Prolonged Fasting: HEREWhat if the prostate treatment your doctor recommended wasn't your only choice?Joel Pruttis came to Dr. Katie Deming with a rising PSA, a lesion seen on his prostate MRI, and a urologist telling him he probably had cancer. But something about it didn't sit right, so he paused, did his research, and made a choice many people in his position may never hear about.Dr. Katie and Joel talk through what it's like to face a scary diagnosis, feel pushed toward a system that doesn't quite feel right, and find the courage to try something different. Joel's story centers on prostate health, but the questions he wrestled with will feel familiar to anyone who has ever wondered if there's another way.Chapters:00:06:17 - Why the MRI Room Changed Everything00:07:09 - Two PSA Numbers, One Big Question00:09:17 - The Reason He Trusted Dr. Katie00:10:09 - The Part of Fasting That Scared Him Most00:11:45 - Why He Took the Leap Anyway00:13:09 - What 14 Days Without Food Actually Felt Like00:14:52 - The Subtle Shift That Told Him It Was Working00:16:13 - The Treatment Path He Almost Walked Into00:23:37 - The Health Changes He Didn't Expect00:29:30 - The Decision That Could Have Changed His Life00:34:40 - The Cost Comparison No One Talks About00:38:47 - The Healing Path Hidden in Plain SightIt's not only about Joel's lab results after a 14-day water fast, but everything else that shifted along the way, things he wasn't even looking for when he started.If you've ever felt stuck between fear and uncertainty, or wondered whether the standard path is really your only option, stay until the end. Joel shares exactly what he would say to anyone standing at that crossroads right now.Press play and learn what happened when one man decided to trust his body first.Join Dr. Katie's 3-Day Guided Fast, for expert support, daily live calls, and a community to fast alongside: Sign-Up Follow Dr. Katie Deming on InstagramWatch on YoutubeDISCLAIMER: The Born to Heal Podcast  is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.A thought-provoking podcast explores cancer through the lens of holistic medicine and functional medicine, discussing causes of cancer, metabolic health, and unconventional approaches like water fasting, fasting and autophagy, and detox, while weighing fasting benefits against chemo side effects and radiation side effects, sharing stories of a cancer survivor navigating chemotherapy, natural medicine, holistic healing, and even spiritual healing on the path toward cancer remission and holistic health. 

Can you really treat prostate cancer effectively without knowing the genetics? In this episode of BackTable Urology, Dr. Evan Yu and Dr. Tanya Dorff join host Dr. Alan Tan to discuss why genetic testing is essential in personalized prostate cancer care. They discuss when and how to perform germline and somatic testing, address common barriers, and share best practices for counseling patients. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction02:18 - Who Gets Somatic Testing?06:43 - Patient Barriers to Testing09:00 - Genetic Testing Workflow12:28 - Treating BRCA2 Alterations24:18 - Monitoring Progression: ctDNA vs. PSA vs. Imaging29:32 - Treating mCRPC with ATM Mutations34:39 - CDK12 Classification 37:43 - Closing Takeaways --- More about this episode The doctors explore how BRCA2 and other DNA repair alterations can directly shape treatment decisions, focusing on the roles of PARP inhibitors and platinum therapy in advanced cases. The discussion highlights why both germline and somatic testing are critical for identifying actionable mutations and discuss the nuances of interpreting test results, including current limitations and emerging biomarkers. They also examine challenges such as insurance coverage, patient misconceptions, and workflow integration, as well as the movement toward truly personalized, biology-driven approaches in prostate cancer care. --- Resources Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial:https://pmc.ncbi.nlm.nih.gov/articles/PMC12705445/ Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study:https://www.annalsofoncology.org/article/S0923-7534(25)04936-1/fulltext Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer:https://www.nejm.org/doi/full/10.1056/NEJMoa1903307 ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patientshttps://www.sciencedirect.com/science/article/pii/S0302283825048766 First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer:https://www.nejm.org/doi/abs/10.1056/NEJMoa2502929 PROMISE Registry:https://www.prostatecancerpromise.org/ Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00683-X/abstract --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Steven Seyedin discusses radiation therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41558]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Steven Seyedin discusses radiation therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41558]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Steven Seyedin discusses radiation therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41558]

Recorded in Chicago, Dr. Aly-Khan Lalani and Dr. Chris Wallis unpack a massive slate of prostate cancer data, fresh from the 2026 ASCO Annual Meeting. The conversation spans the entire disease spectrum, beginning with a deep dive into the PROTEUS trial. Shifting to advanced disease, Dr. Lalani and Dr. Wallis discuss the TALAPRO-3 and the A-DREAM/Alliance A032101 trials. Concluding with a review of sequencing chemotherapy and radioligand therapy in the PLUDO trial, this episode provides an excellent overview of the prostate cancer landscape presented at ASCO 2026.This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Spencer Behr discusses PSMA PET and functional imaging. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41557]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Jonathan Chou discusses targeted therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41563]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Spencer Behr discusses PSMA PET and functional imaging. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41557]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Jonathan Chou discusses targeted therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41563]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Jonathan Chou discusses targeted therapies. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41563]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Spencer Behr discusses PSMA PET and functional imaging. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41557]

Leave a message and let us know what you liked about the episode!Survivor's guilt is a common and not often talked about emotional experience after cancer. Dr. Leah Sherman sits down with returning guest Natasha Ewa, licensed clinical social worker and founder of I Thrive Therapy and Wellness, for an honest conversation about what survivor's guilt actually looks like, why body image after cancer is so personal, and what healing can feel like on the other side.The conversation widens to cover grief over pre-cancer identity, hypervigilance, reconstruction decisions, and Natasha's documentation of her own DIEP flap experience and complications.Whether you're navigating survivorship yourself or supporting someone who is, this one meets you where you are.Visit the I Thrive Therapy and Wellness websiteFollow Natasha on InstagramSupport the showBecome a member of The Cancer Pod Community! Gain access to live Q&As, exclusive content, and so much more! Join us today on Buy Me a Coffee or on Patreon!Check out our website! Looking for more information? We have blogs, merch, and all of our episodes listed by season and category. Shop our favorite reads! We've joined with Bookshop.org to offer some of our fave books!Buy our merch! Whether it's a cozy hoody or a handy water bottle, we have something for everybody.Have a comment or suggestion? Email us at info (at) thecancerpod (dot) com Follow us wherever you browse. We're always @TheCancerPod:InstagramBlueskyFacebookLinkedInYouTubeTHANK YOU!!

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. David Oh discusses immunotherapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41562]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. David Oh discusses immunotherapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41562]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. David Oh discusses immunotherapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41562]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Will Chen discusses PET-directed radiation for Oligometastatic Disease. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41559]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Arpita Desai discusses metastatic hormone sensitive prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41560]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Stacey Kenfield, ScD, discusses diet and exercise. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41555]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Arpita Desai discusses metastatic hormone sensitive prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41560]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Will Chen discusses PET-directed radiation for Oligometastatic Disease. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41559]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Stacey Kenfield, ScD, discusses diet and exercise. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41555]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Arpita Desai discusses metastatic hormone sensitive prostate cancer. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41560]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Will Chen discusses PET-directed radiation for Oligometastatic Disease. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41559]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Stacey Kenfield, ScD, discusses diet and exercise. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41555]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Ivan de Kouchkovsky discusses radioligand therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41561]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Ivan de Kouchkovsky discusses radioligand therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41561]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Ivan de Kouchkovsky discusses radioligand therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41561]

Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Julian Hong discusses radiation therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41551]

As part of the 2026 UCSF Patient Conference on Prostate Cancer, Dr. Julian Hong discusses radiation therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 41551]

If Part 1 was about the field of sexual medicine, Part 2 is about the marriage at the center of it. Dr. Jenni Skyler and Daniel Lebowitz return to their conversation with Dr. Irwin and Sue Goldstein, and this time, the questions get more personal. How do you stay married for fifty years? What does great sex actually look like across the decades? And what happens when a woman who has spent her career in sexual medicine starts experiencing low desire herself? Sue Goldstein opens up about her own journey through peri-menopause and the slow erosion of her libido- what she calls "duty sex", and the medications that brought not just her sex drive back, but a playfulness in her marriage she hadn't realized had gone missing. She walks listeners through her menopause toolbox of five treatments, explains why she's "76 and feels like she's in her 50s", and dismantles the lingering fears from the Women's Health Initiative that have kept generations of women in what she calls hormone prison. Dr. Irwin shares his own daily protocols for sexual health, why he believes most older men are leaving capacity on the table, and the surprising data from their own clinic- that more than half the Vyleesi prescriptions they write are off-label for men. They explore why dopamine is dopamine, regardless of gender. The reality of persistent genital arousal disorder. And a remarkable story of a teenage horseback rider whose chronic arousal turned out to be a herniated disc. This episode is full of practical wisdom, clinical innovation, and one of the most real conversations about long-term love you'll hear all year. The Goldsteins' secret to fifty years of marriage? Best friends, good sex, and the willingness to keep trying new things — including a chocolate sauce on the day before you change the sheets. Irwin Goldstein, MD, IF (he/him/his). Director, San Diego Sexual Medicine 5555 Reservoir Drive, Suite 300, San Diego, CA 92120, Director, Sexual Medicine, UC San Diego Health East Campus, San Diego, CA. Clinical Professor of Urology, University of California at San Diego. Voluntary Clinical Professor of Obstetrics, Gynecology and Reproductive Services Past President, International Society for the Study of Women’s Sexual Health. Past President, Sexual Medicine Society of North America. Editor Emeritus, Sexual Medicine Reviews, The Journal of Sexual Medicine, International Journal of Impotence Research. Phone: 619 265-8865 - Mobile: 619 987-7432. Email: dr.irwingoldstein@gmail.com. http://www.sandiegosexualmedicine.com. Like us on Facebook: https://www.facebook.com/SDSexMed. X: http://twitter.com/SDSexualMedSee omnystudio.com/listener for privacy information.

AUA2026: Focus on: Biomarkers, MRI and PSMA PET Imaging in Prostate Cancer Webcast CME Available: https://cme.auanet.org/URL/FOCUS262ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Critically appraise recent developments in imaging biomarkers and molecular diagnostics (e.g., genomic risk scores, liquid biopsy) and discuss how they complement MRI and PSMA PET in prostate cancer care. 2. Determine the optimal clinical scenarios (diagnostic, staging, recurrence, surveillance) in which PSMA PET/CT or PET/MRI adds value beyond conventional imaging. 3. Recognize potential pitfalls in PSMA PET interpretation — including false positives, false negatives, non–PSMA-expressing disease, and technical artifacts — and implement strategies to mitigate them. 4. Synthesize biomarker, MRI, and PSMA PET findings into a personalized management plan, including guiding biopsy, focal therapy, salvage therapy, or systemic treatments. 5. Select appropriate patients with radiorecurrent or organ-confined prostate cancer for advanced imaging and guide re-treatment decisions (e.g., salvage therapy, targeted radiotherapy). ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Blue Earth Diagnostics, Inc. Lantheus Medical Imaging

This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, challenges, and future directions in radiopharmaceuticals.